{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T20:50:54Z","timestamp":1786308654118,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tumor mutation burden is an emerging biomarker for immunotherapy. Although several clinical trials for immunotherapy in lymphoma have been carried out, the mutation burden of various lymphomas is not well known yet. Thus, the objective of this study was to compare tumor mutation burden of various non-Hodgkin lymphomas using panel based massively parallel sequencing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted 405 gene panel based massively parallel sequencing of 300 non-Hodgkin lymphomas and investigate the number of SNV\/Indel in each lymphoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The number of SNV\/Indel was higher in mature B-cell lymphoma than in mature T- and NK-cell lymphoma. (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) The number of SNV\/Indel in primary mediastinal large B-cell lymphoma and primary diffuse large B-cell lymphoma of the central nervous system was the highest, which was significantly higher than that in diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS).(<jats:italic>P<\/jats:italic>\u2009=\u20090.030 and <jats:italic>P<\/jats:italic>\u2009=\u20090.008, respectively) The SNV\/Indel number in EBV-positive DLBCL NOS was significantly lower than that in DLBCL NOS. (<jats:italic>P<\/jats:italic>\u2009=\u20090.048) Peripheral T-cell lymphoma, NOS showed no significant difference in the number of SNV\/Indel from extranodal NK\/T-cell lymphoma, nasal type (<jats:italic>P<\/jats:italic>\u2009=\u20090.942) or angioimmunoblastic T-cell lymphoma (<jats:italic>P<\/jats:italic>\u2009=\u20090.739). The number of SNV\/Indel in anaplastic large cell lymphoma, ALK-positive was significantly lower than that in anaplastic large cell lymphoma, ALK-negative (<jats:italic>P<\/jats:italic>\u2009=\u20090.049). It was the lowest among all the lymphomas considered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Various lymphomas have different mutation burdens. Thus, tumor mutation burden can be used as a promising biomarker for immunotherapy in lymphomas.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08695-7","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:02:53Z","timestamp":1630321373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing"],"prefix":"10.1186","volume":"21","author":[{"given":"Junhun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hyeh","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"8695_CR1","doi-asserted-by":"publisher","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356. https:\/\/doi.org\/10.1093\/annonc\/mdy495.","DOI":"10.1093\/annonc\/mdy495"},{"key":"8695_CR2","doi-asserted-by":"publisher","unstructured":"Braun DA, Burke KP, Van Allen EM. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clin Cancer Res. 2016;22(23):5642\u201350. https:\/\/doi.org\/10.1158\/1078-0432.","DOI":"10.1158\/1078-0432"},{"key":"8695_CR3","doi-asserted-by":"publisher","unstructured":"Jamieson NB, Maker AV. Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther. 2017;24(3):134\u201340. https:\/\/doi.org\/10.1038\/cgt.2016.63.","DOI":"10.1038\/cgt.2016.63"},{"key":"8695_CR4","doi-asserted-by":"publisher","unstructured":"Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, et al. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2020;25(1):e147\u201359. https:\/\/doi.org\/10.1634\/theoncologist.2019-0244.","DOI":"10.1634\/theoncologist.2019-0244"},{"key":"8695_CR5","doi-asserted-by":"publisher","unstructured":"Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28(8):411\u20139. https:\/\/doi.org\/10.1093\/intimm\/dxw019.","DOI":"10.1093\/intimm\/dxw019"},{"key":"8695_CR6","doi-asserted-by":"publisher","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321. https:\/\/doi.org\/10.1038\/nature22991.","DOI":"10.1038\/nature22991"},{"key":"8695_CR7","doi-asserted-by":"publisher","unstructured":"Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125(10):3981\u201391. https:\/\/doi.org\/10.1172\/JCI82416.","DOI":"10.1172\/JCI82416"},{"key":"8695_CR8","doi-asserted-by":"publisher","unstructured":"Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019;8(9):e1629258. https:\/\/doi.org\/10.1080\/2162402X.2019.1629258.","DOI":"10.1080\/2162402X.2019.1629258"},{"key":"8695_CR9","doi-asserted-by":"publisher","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386.","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"8695_CR10","doi-asserted-by":"publisher","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","DOI":"10.1126\/science.aar4060"},{"key":"8695_CR11","doi-asserted-by":"publisher","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"8695_CR12","doi-asserted-by":"publisher","unstructured":"Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313\u201325. https:\/\/doi.org\/10.1111\/bjh.12380.","DOI":"10.1111\/bjh.12380"},{"key":"8695_CR13","doi-asserted-by":"publisher","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2.","DOI":"10.1186\/s13073-017-0424-2"},{"key":"8695_CR14","doi-asserted-by":"publisher","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313. https:\/\/doi.org\/10.1038\/nm.4333.","DOI":"10.1038\/nm.4333"},{"issue":"7463","key":"8695_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321. https:\/\/doi.org\/10.1038\/nature12477.","journal-title":"Nature."},{"key":"8695_CR16","doi-asserted-by":"publisher","unstructured":"Wang X, Li M. Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunol. 2019;20(1):4. https:\/\/doi.org\/10.1186\/s12865-018-0285-5.","DOI":"10.1186\/s12865-018-0285-5"},{"issue":"3","key":"8695_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/carcin\/21.3.379","volume":"21","author":"KR Loeb","year":"2000","unstructured":"Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis. 2000;21(3):379\u201385. https:\/\/doi.org\/10.1093\/carcin\/21.3.379.","journal-title":"Carcinogenesis."},{"issue":"3","key":"8695_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1073\/pnas.0334858100","volume":"100","author":"LA Loeb","year":"2003","unstructured":"Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci. 2003;100(3):776\u201381. https:\/\/doi.org\/10.1073\/pnas.0334858100.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"8695_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity. 2004;21(2):137\u201348. https:\/\/doi.org\/10.1016\/j.immuni.2004.07.017.","journal-title":"Immunity."},{"key":"8695_CR20","doi-asserted-by":"publisher","unstructured":"Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135(8):523\u201333. https:\/\/doi.org\/10.1182\/blood.2019000847.","DOI":"10.1182\/blood.2019000847"},{"key":"8695_CR21","doi-asserted-by":"publisher","unstructured":"Heyman B, Yang Y. New developments in immunotherapy for lymphoma. Cancer Biol Med. 2018;15(3):189\u2013209. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0037.","DOI":"10.20892\/j.issn.2095-3941.2018.0037"},{"key":"8695_CR22","doi-asserted-by":"publisher","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1411087.","DOI":"10.1056\/NEJMoa1411087"},{"key":"8695_CR23","doi-asserted-by":"publisher","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X.","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"8695_CR24","doi-asserted-by":"publisher","unstructured":"Bek\u00f6z H, Karadurmu\u015f N, Payda\u015f S, T\u00fcrker A, Topta\u015f T, F\u0131ratl\u0131 Tu\u011flular T, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol. 2017;28(10):2496\u2013502. https:\/\/doi.org\/10.1093\/annonc\/mdx341.","DOI":"10.1093\/annonc\/mdx341"},{"key":"8695_CR25","doi-asserted-by":"publisher","unstructured":"Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S, et al. PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133(22):2401\u201312. https:\/\/doi.org\/10.1182\/blood.2018889931.","DOI":"10.1182\/blood.2018889931"},{"key":"8695_CR26","doi-asserted-by":"publisher","unstructured":"Tomassetti S, Chen R, Dandapani S. The role of pembrolizumab in relapsed\/refractory primary mediastinal large B-cell lymphoma. Ther Adv Hematol. 2019;10:2040620719841591. https:\/\/doi.org\/10.1177\/2040620719841591.","DOI":"10.1177\/2040620719841591"},{"key":"8695_CR27","volume-title":"WHO classification of Tumours of Haematopoietic and lymphoid tissues. Revised 4th edition ed","author":"SHCE Swerdlow","year":"2017","unstructured":"Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of Tumours of Haematopoietic and lymphoid tissues. Revised 4th edition ed. Lyon: IARC; 2017."},{"key":"8695_CR28","unstructured":"IGSR: The International Genome Sample Resource. http:\/\/www.internationalgenome.org\/."},{"key":"8695_CR29","unstructured":"gnomAD. https:\/\/gnomad.broadinstitute.org\/."},{"key":"8695_CR30","unstructured":"NHLBI Grand Opportunity Exome Seqeuncing Project (ESP). https:\/\/esp.gs.washington.edu\/drupal\/."},{"key":"8695_CR31","doi-asserted-by":"publisher","unstructured":"Jung KS, Hong KW, Jo HY, Choi J, Ban HJ, Cho SB, Chung M. KRGDB: the large-scale variant database of 1722 Koreans based on whole genome sequencing. Database (Oxford). 2020;2020:baz146. https:\/\/doi.org\/10.1093\/database\/baz146.","DOI":"10.1093\/database\/baz146"},{"key":"8695_CR32","unstructured":"KOVA. https:\/\/www.kobic.re.kr\/kova\/."},{"key":"8695_CR33","doi-asserted-by":"publisher","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382. https:\/\/doi.org\/10.1182\/blood-2003-05-1545.","DOI":"10.1182\/blood-2003-05-1545"},{"issue":"6","key":"8695_CR34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/tlcr.2018.08.02","volume":"7","author":"B Mel\u00e9ndez","year":"2018","unstructured":"Mel\u00e9ndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D'Haene N. Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res. 2018;7(6):661\u20137. https:\/\/doi.org\/10.21037\/tlcr.2018.08.02.","journal-title":"Transl Lung Cancer Res"},{"key":"8695_CR35","doi-asserted-by":"publisher","unstructured":"Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147. https:\/\/doi.org\/10.1136\/jitc-2019-000147.","DOI":"10.1136\/jitc-2019-000147"},{"key":"8695_CR36","doi-asserted-by":"publisher","unstructured":"Endris V, Buchhalter I, Allg\u00e4uer M, Rempel E, Lier A, Volckmar AL, et al. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer. 2019;144(9):2303\u201312. https:\/\/doi.org\/10.1002\/ijc.32002.","DOI":"10.1002\/ijc.32002"},{"key":"8695_CR37","doi-asserted-by":"publisher","unstructured":"Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183. https:\/\/doi.org\/10.1186\/s40425-019-0647-4.","DOI":"10.1186\/s40425-019-0647-4"},{"key":"8695_CR38","doi-asserted-by":"publisher","unstructured":"Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, K\u00fcppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341\u20136. https:\/\/doi.org\/10.1038\/35085588.","DOI":"10.1038\/35085588"},{"key":"8695_CR39","doi-asserted-by":"publisher","unstructured":"Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851\u201362. https:\/\/doi.org\/10.1084\/jem.20031074.","DOI":"10.1084\/jem.20031074"},{"key":"8695_CR40","doi-asserted-by":"publisher","unstructured":"Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871\u20139. https:\/\/doi.org\/10.1182\/blood-2003-06-1841.","DOI":"10.1182\/blood-2003-06-1841"},{"key":"8695_CR41","doi-asserted-by":"publisher","unstructured":"Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019;37(34):3291\u20139. https:\/\/doi.org\/10.1200\/JCO.19.01389.","DOI":"10.1200\/JCO.19.01389"},{"key":"8695_CR42","doi-asserted-by":"publisher","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268\u201377. https:\/\/doi.org\/10.1182\/blood-2010-05-282780.","DOI":"10.1182\/blood-2010-05-282780"},{"key":"8695_CR43","doi-asserted-by":"publisher","unstructured":"Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062\u20135. https:\/\/doi.org\/10.1182\/blood-2013-10-535443.","DOI":"10.1182\/blood-2013-10-535443"},{"key":"8695_CR44","doi-asserted-by":"publisher","unstructured":"Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia. 2008;22(2):400\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2405019.","DOI":"10.1038\/sj.leu.2405019"},{"key":"8695_CR45","doi-asserted-by":"publisher","unstructured":"Graber JJ, Plato B, Mawad R, Moore DJ. Pembrolizumab immunotherapy for relapsed CNS Lymphoma. Leuk Lymphoma. 2020;61(7):1766\u20138. https:\/\/doi.org\/10.1080\/10428194.2020.1742903.","DOI":"10.1080\/10428194.2020.1742903"},{"key":"8695_CR46","doi-asserted-by":"publisher","unstructured":"Choi IK, Wang Z, Ke Q, Hong M, Qian Y, Zhao X, et al. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses. Proc Natl Acad Sci U S A. 2018;115(4):E686\u201395. https:\/\/doi.org\/10.1073\/pnas.1713607115.","DOI":"10.1073\/pnas.1713607115"},{"key":"8695_CR47","doi-asserted-by":"publisher","unstructured":"Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59\u201373. https:\/\/doi.org\/10.1038\/cr.2016.153.","DOI":"10.1038\/cr.2016.153"},{"key":"8695_CR48","doi-asserted-by":"publisher","unstructured":"Gru AA, Haverkos BH, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, et al. The Epstein-Barr virus (EBV) in T cell and NK cell lymphomas: time for a reassessment. Curr Hematol Malignancy Rep. 2015;10(4):456\u201367. https:\/\/doi.org\/10.1007\/s11899-015-0292-z.","DOI":"10.1007\/s11899-015-0292-z"},{"key":"8695_CR49","doi-asserted-by":"publisher","unstructured":"Huang Y, de Reyni\u00e8s A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226\u201337. https:\/\/doi.org\/10.1182\/blood-2009-05-221275.","DOI":"10.1182\/blood-2009-05-221275"},{"key":"8695_CR50","doi-asserted-by":"publisher","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais J-P, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148\u2013e51. https:\/\/doi.org\/10.3324\/haematol.2016.158428.","DOI":"10.3324\/haematol.2016.158428"},{"key":"8695_CR51","doi-asserted-by":"publisher","unstructured":"Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. Br J Haematol. 2015;168(6):771\u201383. https:\/\/doi.org\/10.1111\/bjh.13265.","DOI":"10.1111\/bjh.13265"},{"key":"8695_CR52","doi-asserted-by":"crossref","unstructured":"Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913\u201321.","DOI":"10.1182\/blood.V93.11.3913.411k22_3913_3921"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08695-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:04:53Z","timestamp":1630321493000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08695-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8695"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08695-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with Helsinki declaration, and all protocols of this study were approved by the Institutional Review Board of Samsung Medical Center (IRB file number: SMC 2021\u201302-065).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"972"}}